NEW YORK, Feb. 8, 2013 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today that trading of Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapeutics, commenced on The NASDAQ Stock Market on January 29, 2013.
Stemline is developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline a leader in the CSC field, is developing the most clinically advanced pipeline of anti-CSC therapeutics, and possesses a broad portfolio of CSC-focused intellectual property. The Company is currently developing two late stage clinical product candidates, SL-401 and SL-701, both of which have demonstrated clinical activity, including durable complete responses (CRs), and an overall survival (OS) benefit versus historical controls in Phase 1/2 studies of advanced cancer patients.
"Stemline Therapeutics, Inc. is a company focused on developing innovative therapeutics for a wide variety of cancer types," said Bob McCooey, Senior Vice President, NASDAQ OMX Corporate Client Group. "We are proud to welcome Stemline to the NASDAQ family and look forward to supporting their endeavors as a public company."
Since its inception, NASDAQ OMX has consistently been the exchange of choice for progressive and cutting-edge health care and biopharmaceutical companies. NASDAQ currently lists 83 percent of public biotechnology and pharmaceutical companies on US markets, and welcomed 11 biotechnology and pharmaceutical companies to its markets in 2012.
About NASDAQ OMX:
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 25 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (http://www.facebook.com/NASDAQ) and Twitter (http://www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500)
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding NASDAQ-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
CONTACT: Jennifer Knapp +1 212 401 8916 Jennifer.Knapp@nasdaqomx.com
|Stemline Therapeutics, Inc. Announces Closing of Initial Public Offering (2013/1/31)|
|Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, Japan (2013/4/8)|
|Stemline Therapeutics, Inc. Announces Exercise of Over-Allotment Option (2013/1/29)|
|Stemline Therapeutics, Inc. to Present at BIO CEO & Investor Conference on February 11th (2013/2/7)|
|Photo Release -- NASDAQ Welcomes Independent Bank Group to the NASDAQ Global Market(R) (2013/4/3)|
|EBOD Announces Intention to Voluntarily Delist From the Nasdaq Stock Market and Deregister as a Reporting Company With the SEC (2013/2/1)|
|Health Insurance Innovations, Inc. [HIIQ] to Ring The NASDAQ Stock Market Closing Bell in Celebration of Its Initial Public Offering (IPO) (2013/2/8)|
|Pacira Pharmaceuticals, Inc. to Close The NASDAQ Stock Market on April 8, 2013 (2013/4/5)|
|The NASDAQ Stock Market Tops U.S. Exchanges in IPOs and Transfers in Q1 2013 (2013/4/4)|
|Vanguard Natural Resources, LLC to Switch Stock Exchange Listing to The NASDAQ Stock Market (2013/4/11)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.